期刊文献+

浅谈动物源性医疗器械的产业发展和监管现状 被引量:9

An Overview on Industrial Development and Regulations for Animal-derived Medical Devices
下载PDF
导出
摘要 目的为动物源性医疗器械产业发展、法律法规建设和标准体系的完善提供参考。方法介绍了动物源性医疗器械产业发展的现状和趋势;概述了相关法规要求和现行标准体系;重点阐述了相关法规和标准中对风险控制的通用技术要求;同时分析了动物源性医疗器械特殊的免疫毒性风险和免疫毒性评价中技术的瓶颈问题。结果与结论动物源性医疗器械的产品种类、应用范围呈现不断增加趋势,为相关生产企业、研究人员、检测与监管人员提供综合信息具有重要的现实意义。 medical devices Objective To provide references for the derived from animals and the gradual development of the manufacturing industry of perfection of relevant laws, regulations and systematic standards. Methods This review outlined the current development and trend of the manufacturing industry of medical devices derived from animals, summarized the relevant statutory requirements and the current systematic standards. Special efforts were devoted to explaining the general technical requirements for controlling risks under the regulations and standards. In addition, it analyzed the special immunotoxicity risks posed by medical devices derived from animals and the bottleneck issues for the immune toxicity evaluation technology. Results and Conclusion The types of medical devices derived from animals are continuously on the rise with expanding application range. In this background, this paper provided comprehensive information not only for the manufacturers and researchers, but also for the supervisors and experts who perform the pre-clinical evaluation or registration evaluation.
出处 《中国药事》 CAS 2013年第8期779-786,共8页 Chinese Pharmaceutical Affairs
基金 再生型医用植入器械国家工程实验室首席专家项目 (编号2012NELRMD002)
关键词 动物源性医疗器械 标准 法规 免疫毒性 技术要求 animal-derived medical devices standards regulations immunotoxicity technical requirement
  • 相关文献

参考文献43

  • 1史新立,谭芳奕,王召旭,奚廷斐,解慧琪,杨志明,戴建武.疯牛病病原体研究及动物源性医疗器械产品安全性思考[J].中国修复重建外科杂志,2006,20(11):1138-1144. 被引量:25
  • 2Badylak SF, Gilbert TW. Immune Response to Biologic Scaffold Materials [J]. Semin Immunol, 2008, 20 (2): 109- 116.
  • 3由少华.动物源原料医疗器械病毒和传染因子携带风险的监控[J].中国医疗器械杂志,2004,28(5):356-358. 被引量:9
  • 4FDA. Guidance for Industry: The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongi- form Encephalopathy (BSE) in FDA Regulated Products for Human Use [S]. 1997.
  • 5FDA. Guidance for FDA Reviewers and Industry= Medical Devices Containing Materials Derived from Animal Sources (Except for In Vitro Diagnostic Devices) [S] . 1998.
  • 6Animal tissues and their derivatives utilized in the manufac ture of medical devices Part1: Analysis and management of risk [S]. EN 12442-1, 2001, 2001.
  • 7Animal tissues and their derivatives utilized in the manufae- ture of medical devices Part2= Controls on sourcing, collee tion and handing [SJ. EN 12442 2: 2001, 2001.
  • 8Animal tissues and their derivatives utilized in the manufae ture of medical devices-Part3= Validation of the eliraination and/or inactivation of viruses and transmissible agents [S]. EN 12442 3: 2001, 2001.
  • 9A Guide /or Manufacturers and Notified Bodies: Application of Council Directive 93/42/EEC Taking into Account the Commission Directive 2003/32/EC for Medical Devices Utili zing Tissues or Derivatives Originating from Animal for Which a TSE Risk is Suspected [S]. MEDDEV. 2.11 / lrev. 1, February 2004, 2004.
  • 10Medical devices utilizing animal tissues and their derivatives - Part 1: Application of risk management [S]. ISO 22442 1: 2007, 2007.

二级参考文献28

共引文献24

同被引文献83

引证文献9

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部